(via NewsDirect)
Willow Bioscience CEO Dr
The partnership is focused on optimizing cell line productivity for manufacturing a high-volume anti-infective Active Pharmaceutical Ingredient (API) using precision fermentation. Savile explained that Suanfarma will gain access to
Suanfarma is a contract development and manufacturing organization (CDMO) with a strong track record and expertise in fermentation, purification, and chemical synthesis technologies. Its commitment to maintaining the highest quality standards in pharmaceutical and biotech manufacturing makes it an ideal partner for this collaboration.
The agreement reflects both companies' dedication to advancing biotechnology solutions for pharmaceutical production.
Contact Details
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source